Protein Phosphatase-1 Activates CDK9 by Dephosphorylating Ser175 by Ammosova, Tatiana et al.
Protein Phosphatase-1 Activates CDK9 by
Dephosphorylating Ser175
Tatiana Ammosova
1,2, Yuri Obukhov
1,2, Alexander Kotelkin
1, Denitra Breuer
1,3, Monique Beullens
4,
Victor R. Gordeuk
1, Mathieu Bollen
4, Sergei Nekhai
1,2,3*
1Center for Sickle Cell Disease, Howard University, Washington, D.C., United States of America, 2RCMI Proteomics Core Facility, Howard University, Washington, D.C.,
United States of America, 3Department of Microbiology, Howard University, Washington, D.C., United States of America, 4Department of Molecular Cell Biology, Catholic
University of Leuven, Leuven, Belgium
Abstract
The cyclin-dependent kinase CDK9/cyclin T1 induces HIV-1 transcription by phosphorylating the carboxyterminal domain
(CTD) of RNA polymerase II (RNAPII). CDK9 activity is regulated by protein phosphatase-1 (PP1) which was previously shown
to dephosphorylate CDK9 Thr186. Here, we analyzed the effect of PP1 on RNAPII phosphorylation and CDK9 activity. The
selective inhibition of PP1 by okadaic acid and by NIPP1 inhibited phosphorylation of RNAPII CTD in vitro and in vivo.
Expression of the central domain of NIPP1 in cultured cells inhibited the enzymatic activity of CDK9 suggesting its activation
by PP1. Comparison of dephosphorylation of CDK9 phosphorylated by (
32P) in vivo and dephosphorylation of CDK9’s Thr186
analyzed by Thr186 phospho-specific antibodies, indicated that a residue other than Thr186 might be dephosphorylated by
PP1. Analysis of dephosphorylation of phosphorylated peptides derived from CDK9’s T-loop suggested that PP1
dephosphorylates CDK9 Ser175. In cultured cells, CDK9 was found to be phosphorylated on Ser175 as determined by
combination of Hunter 2D peptide mapping and LC-MS analysis. CDK9 S175A mutant was active and S175D – inactive, and
dephosphorylation of CDK9’s Ser175 upregulated HIV-1 transcription in PP1-dependent manner. Collectively, our results
point to CDK9 Ser175 as novel PP1-regulatory site which dephosphorylation upregulates CDK9 activity and contribute to
the activation of HIV-1 transcription.
Citation: Ammosova T, Obukhov Y, Kotelkin A, Breuer D, Beullens M, et al. (2011) Protein Phosphatase-1 Activates CDK9 by Dephosphorylating Ser175. PLoS
ONE 6(4): e18985. doi:10.1371/journal.pone.0018985
Editor: David Harrich, Queensland Institute of Medical Research, Australia
Received September 15, 2010; Accepted March 24, 2011; Published April 21, 2011
Copyright:  2011 Ammosova et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This project was supported by National Institutes of Health (NIH) Research Grants 2 R25 HL003679-08 (to VRG) funded by the National Heart, Lung, and
Blood Institute and The Office of Research on Minority Health; 2MO1 RR10284 (to VRG), 1SC1GM082325-01 (to SN); by Howard University Seed Grant (to SN),
RCMI-NIH 2G12RR003048 (to SN) from the Research Centers in Minority Institutions (RCMI) Program (Division of Research Infrastructure, National Center for
Research Resources, NIH) and by Howard University-Sponsored New Faculty Research Start-up Funds Program. This work was additionally supported by the Fund
for Scientific Research-Flanders (Grant G.0478.08), a Flemish Concerted Research Action (GOA 10/16) and the Prime Minister’s office (IAP-P6/28P). The funders had
no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: snekhai@howard.edu
Introduction
CDK9/cyclin T1 is a protein kinase that phosphorylates the C-
terminal domain (CTD) of the largest subunit of RNA
polymerase II (RNAPII) [1]. CDK9/cyclin T1 is found within
large and small molecular weight complexes. The large complex
contains 7SK RNA [2,3], the hexamethylene bisacetamide
(HEXIM1) protein [4,5] and recently identified La-related
LARP7 protein [6,7,8] and methylphosphatase capping enzyme
MePCE [9,10]. The activity of CDK9 in the large complex is
inhibited by interaction with 7SK RNA and HEXIM1 [2,3,4,5].
In contrast, the small complex is devoid of 7SK RNA and
HEXIM1 protein, and contains enzymatically active CDK9
[2,3]. Association of CDK9/cyclin T1 with 7SK RNA/HEXIM1
is mediated by phosphorylation of CDK9 on Thr186, which is
also required for the enzymatic activity of CDK9 [11,12]. In
addition to Thr186, several serine and threonine residues in
CDK9 can be phosphorylated. These residues include N-terminal
Thr29 [13]; T-loop Ser175 [12,14], and the C-terminal residues
Ser329, Thr330, Thr333, Ser334, Ser347, Thr350, Ser353, and
Thr354, collectively referred to as ‘C8’ [12,15]. The Thr29 and
C8 residues are autophosphorylated [12,13,15]. Earlier in vitro
studies showed that CDK9 autophosphorylation on C8 residues
was prerequisite for the binding of CDK9/cyclin T1 to TAR
RNA [15,16]. Previously, we showed that CDK9 autopho-
sphorylated in vitro is dephosphorylated by protein phosphatase
2A (PP2A) but not protein phosphatase-1 (PP1) [17]. Also, PP2A
but not PP1 prevented the binding of CDK9/cyclin T1 to TAR
RNA and Tat [17] confirming previous observation that CDK9
autophosphorylation is needed for its binding to TAR RNA
[15,16]. Contrary to the strong CDK9 dephosphorylation by
PP2A in vitro, inhibition of PP2A in vivo had little effect on CDK9
phosphorylation and HIV-1 transcription which is sensitive to
CDK9. On the other hand, inhibition of PP1 in vivo strongly
increased CDK9 phosphorylation and profoundly inhibited Tat-
activated HIV-1 transcription [17]. The strong effect of PP1 in
vivo suggested that unlike the situation in vitro, CDK9 might be
dephosphorylated by PP1 in the cells and that PP1 might have a
regulatory role in HIV-1 transcription. Indeed, we previously
showed that PP1 expression induced HIV-1 transcription in
cultured cells [18] and expression of PP1 inhibitor, NIPP1,
inhibited Tat-induced HIV-1 transcription and replication
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PP1 might dephosphorylate CDK9 residue(s) other that those
shown to be autophosphorylated in vitro, i.e Thr29 and C8
residues. One plausible candidate for PP1 dephosphorylation is
CDK9 T-loop that includes Ser175 and Thr186 residues.
Recently, CDK9 activation in stress-induced cells was shown to
be cooperatively induced by PP1a and protein phosphatase 2B
(PP2B) [21]. PP1a was shown to dephosphorylate Thr186 and
disrupt the interaction between CDK9/cyclin T1 and 7SK
RNA/HEXIM1 [21]. In the present paper, we show that PP1
inhibition in cell extracts in vitro and in cultured cells reduced
RNAPII CTD phosphorylation and the activity of CDK9, which
indicated that PP1 is an activator of CDK9. Comparison of
dephosphorylation of CDK9 phosphorylated by (
32P) in vivo and
dephosphorylation of CDK9’s Thr186 analyzed by Thr186
phospho-specific antibodies, indicated that a residue other than
Thr186 might be dephosphorylated by PP1. Analysis of
dephosphorylation of phosphorylated peptides derived from
CDK9’s T-loop and also in vivo phosphorylated CDK9 with
Ser175 mutation showed that Ser175 could be dephosphorylated
by PP1 in vitro. Further analysis of CDK9 phosphorylation
residues was carried by Hunter 2D peptide mapping and LC-MS,
pointing to CDK9 Ser 175 as one of the two phosphorylation
sites. Analysis of the activity of CDK9’s S175A and S175D
mutants showed that CDK9 S175A mutant was active and
S175D - inactive. Expression of cdNIPP1 prevented the
interaction of CDK9 S175D with HEXIM1. Analysis of the
effect of CDK9 point mutations alone or in combination with
PP1 on HIV-1 transcription which is dependent on CDK9,
indicate that dephosphorylation of CDK9’s Ser175 upregulated
HIV-1 transcription in PP1-dependent manner. Collectively, our
results point to Ser175 as PP1-regulatory site in CDK9 which
dephosphorylation upregulates CDK9 activity and may contrib-
ute to the regulation of HIV-1 transcription.
Results
Inhibition of PP1 prevents RNAPII CTD phosphorylation
in vitro
We previously showed that after the inhibition of RNAPII
CTD kinases by flavopiridol, the RNAPII CTD is quickly
dephosphorylated by PP1 [22]. Here, we conducted an opposite
experiment, that is we inhibited PP1 and then analyzed RNAPII
CTD phosphorylation. RNAPII was phosphorylated in an in
vitro transcription reaction and itsp h o s p h o r y l a t i o nw a sv i s u a l -
ized by immunoblotting with phospho-epitope specific mono-
clonal antibodies that recognized phospho Ser-2 residues in the
heptapeptide repeats of the CTD (Fig. 1A, compare lanes 1 and
2). Addition of 10 nM okadaic acid, a concentration inhibitory
for PP2A [17], did not change RNAPII CTD phosphorylation
(Fig. 1A, lane 3). In contrast, a strong decrease in the
phosphorylation of the CTD of RNAPII was observed in the
presence of 1 mM okadaic acid, which is inhibitory to both
PP2A and PP1 (Fig. 1A, lane 4), su g g e s t i n gt h a ti n h i b i t i o no f
PP1 in the nuclear extract inhibited an RNAPII-directed kinase.
To verify that the inhibition ofR N A P I Ip h o s p h o r y l a t i o nw a s
due to the inhibition of PP1, recombinant NIPP1, a potent and
specific inhibitor of PP1 [22], was added to the nuclear extract.
This resulted in the reduction of Ser-2 phosphorylation of
RNAPII (Fig. 1B, lane 3). These results demonstrated that
specific inhibition of PP1 in nuclear extract reduced the level of
RNAPII phosphorylation and this is more likely the inhibition of
a kinase rather than the direct RNAPII CTD dephosphorylation
of PP1.
Inhibition of PP1 prevents RNAPII CTD phosphorylation
in cultured cells
We extended the in vitro observation to the cultured cells by
examining the effect of PP1 inhibition on the dynamic RNAPII
phosphorylation. The RNAPII phosphorylation was measured by
the incorporation of radioactive (
32P) into the RNAPII in cultured
cells. 293T cells were transfected with vectors expressing an
inhibitory fragment of NIPP1 (cdNIPP1 wt) or the corresponding
PP1 binding mutant (V201A/F203A, mut) [23]. At 24 hours post-
transfection, cells were pulsed with (
32P) orthophosphate for 3 hrs
and also treated with 0.1 mM okadaic acid to inhibit PP1. RNAPII
was immunoprecipitated from the cell lysates and its phosphoryla-
tion was analyzed. Expression of cdNIPP1 reduced the incorpora-
tion of (
32P) into RNAPII (Fig. 1C, lane 2) in comparison to the
mock-transfected or cdNIPP1 mut transfected cells (Fig. 1C, lanes 1
and 3). Thus, the inhibition of PP1 affects the phosphorylation of
RNAPII CTD both in vitro and in cultured cells.
PP1 dephosphorylates CDK9 that was metabolically
labeled with (
32P) in cultured cells
We previously showed that inhibition of PP1 in cultured cells
increased CDK9 phosphorylation [17], suggesting that PP1 may
dephosphorylate CDK9. To analyze CDK9 dephosphorylation
directly, we metabolically labeled endogenous CDK9 in vivo. FLAG-
tagged CDK9 was expressed in 293T cells and phosphorylated by a
pulse with (
32P) orthophosphate and also by the addition of 0.1 mM
okadaic acid to inhibit cellular PP1 [17]. The (
32P)-phosphorylated
FLAG-CDK9 was immunoprecipitated and subjected to dephos-
phorylation by PP1, PP2A and, as a control, Cdc25, a dual-
specificity phosphatase that dephosphorylates Thr14 and Tyr15
residues of CDK2 [24]. Phosphorylated CDK9 was efficiently
dephosphorylated by PP1, but not by PP2A or Cdc25A (Fig. 2A).
Because recombinant phosphatases in vitro may not be specific
toward their substrates, we compared PP1 and PP2A with a
commercially available substrate, KR-pT-IRR peptide (Millipore)
or a specially designed PP1 substrate, phospho-Rb peptide (HIPR-
pS-PYKFPS-pS-PLR). While PP1 and PP2A both dephosphory-
lated the KR-pT-IRR peptide with PP2A being somewhat more
efficient (Fig. 2B), only PP1 dephosphorylated the phospho-Rb
peptide (Fig. 2B), confirming that PP1 and PP2A displayed distinct
substrate specificity. Thus PP1 and not PP2A specifically dephos-
phorylated CDK9 that was phosphorylated in vivo.
PP1 targets other residues of CDK9 in addition to Thr186
To analyze whether Thr186 of CDK9 was the only target site
for PP1 dephosphorylation, FLAG-CDK9 wild type (WT) or the
T186A mutant were expressed in 293T cells. Subsequently, the
cells were treated with okadaic acid, CDK9 was immunoprecip-
itated with anti-FLAG antibodies from the cell lysates and the
immunoprecipitates were subjected to dephosphorylation by PP1
or PP2A. In contrast to the almost complete dephosphorylation of
(
32P)-labeled CDK9 by PP1 (Fig. 2A), dephosphorylation of Thr
186 was partial (Fig. 2C, lane 2), suggesting that PP1 might target
additional phosphorylation sites in CDK9. Combined results from
independent experiments show that (
32P)-labeled CDK9 is more
efficiently dephosphorylated by PP1 than the Thr186-phosphor-
ylated CDK9 (Fig. 2D).
PP1 dephosphorylates CDK9 on Ser 175
We analyzed dephosphorylation of CDK9’s T-loop using a
synthetic peptide that spans the T-loop of CDK9 (
172RAF-
SLAKNSQPNRYTNRVV
190) and comprised both Ser175 and
Thr 186 residues. We also used alanine mutants of Ser175 (S175A:
Protein Phosphatase-1 Activates CDK9
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190), Thr186 (T186A:
172RAF-
SLAKNSQPNRYANRVV
190) or both residues (S175A/T186A:
172RAFALAKNSQPNRYANRVV
190). The T-loop-derived WT
CDK9 and CDK9 T186A peptides were efficiently phosphory-
lated by whole cell extracts whereas the S175A peptide and the
double mutated S175A/T186A peptide were not phosphorylated
suggesting that Ser175 but not Thr186 kinase activity was present
abundantly in the cell extract (data not shown). Previously,
CDK9/cyclin T1 was shown to autophosphorylate its T-loop
[25]. Also, CDK2/cyclin E is known to phosphorylate the
T-loop of CDK7 [26]. Indeed, recombinant CDK2/cyclin E
efficiently phosphorylated the T-loop peptides of CDK7 (WT:
150KSFGSPNRIYTHQVV
165; T160A:
150KSFGSPNRIYAHQVV
165)
(Fig.3A,lanes1 and2),but wasnotabletophosphorylatethe T-loop
of CDK9 (Fig. 3A, lane 3). In contrast, recombinant CDK9/cyclin
T1 phosphorylated both WT and the T186A mutant peptides
(Fig. 3A, lanes 4 and 6), but to a lesser extent the S175A peptide
(Fig. 3A, lane 5). CDK9/cyclin T1 did not phosphorylate the S175/
T186A mutant (Fig. 3A, lane 7) ruling out the phosphorylation of an
additional serine residue, Ser180, that is also present in the T-loop
peptide.ToanalyzethedephosphorylationofSer175byPP1,WTor
T186A mutant T-loop peptides were first phosphorylated by
recombinantCDK9/cyclin T1,then the CDK9activity was blocked
by the addition of the CDK9 inhibitor ARC (1 mM, [27]) (Fig. 3B,
lanes 1 and 4). Dephosphorylation of the CDK9-phosphorylated
WT and T186A peptides showed that both of these peptides were
efficiently dephosphorylated by PP1 (Fig. 3B, lanes 2, 3, 5 and 6).
Together these results suggest that Ser175 is efficiently phosphor-
ylated by an abundant kinase activity that may include CDK9/
cyclin T1 and that Ser175 is dephosphorylated by PP1 in vitro.
CDK9 is phosphorylated on Ser175 in vivo
Previously, analysis of recombinant CDK9 revealed phosphor-
ylation of Thr186 [25,28]. Interestingly, in both reports, only
Figure 1. Inhibition of PP1 prevents RNAPII CTD phosphorylation and inhibits CDK9 activity. (A) High concentration of okadaic acid
inhibits RNAPII phosphorylation in vitro. HeLa cell nuclear extract was subjected to in vitro transcription without (lane 2) or with the addition of
10 nM okadaic acid (lane 3) or 1 mM okadaic acid (lane 4). Lane 1, untreated HeLa cell nuclear extract. RNAPII was resolved on 5% SDS-PAGE and
analyzed with RNAPII CTD serine 2 phospho-epitope specific antibodies (Ser2). (B) NIPP1 prevents RNAPII phosphorylation in vitro. HeLa cell
nuclear extract was subjected to in vitro transcription without (lane 2) or with the addition of 5 mM NIPP1 (lane 3). Lane 1, untreated HeLa cell nuclear
extract. RNAPII was resolved on 5% SDS-PAGE and analyzed with Ser2 phospho-epitope specific antibodies. (C) Expression of cdNIPP1 prevents
RNAPII phosphorylation in cultured cells. 293T cells were transfected with vectors expressing wt cdNIPP1 (lane 2) or mutant cdNIPP1 (lane 3) or
mock transfected (lane 1). At 48 hours post transfection, the cells were treated with 0.1 mM okadaic acid and pulsed with (
32P) orthophosphate for
3 hours. The cellular lysates were subjected to immunoprecipitation with 8WG16 antibodies against RNAPII CTD (lanes 1 to 3) or with non-specific
mouse IgG2a (lane 4). Immunoprecipitated RNAPII was resolved on 5% SDS-PAGE and the gel was analyzed on Phosphor Imager. Separately, RNAPII
was immunoprecipitated and analyzed by Western blotting (lower panel). (D&E ) Expression of cdNIPP1 inhibits enzymatic activity of CDK9.
Lysates of 293T cells (lane 1) or 293T cells continuously expressing cdNIPP1 (293T-cdNIPP1 cells) (lane 2) were immunoprecipitated with anti-CDK9
antibodies. Precipitated CDK9 was supplemented with c-(
32P) ATP and purified yeast RNAPII (panel D) or GST-CTD (panel E) as substrates. GST-CTD
and RNAPII were resolved on 10% and 7.5% SDS-PAGE gels and the gels were analyzed on Phosphor Imager. Immunoprecipitation of CDK9 was
verified by immunoblotting (lower panel D). Also there was phosphorylation in the absence of substrate ((lower panel E) or when non-specific
antibodies were used (panel E, lanes 3 and 4). Results are from a typical experiment of 2–4 performed.
doi:10.1371/journal.pone.0018985.g001
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186NR peptide was detected
whereas fully hydrolyzed YpT
186NR peptide was not seen. We
conducted LC-MS/MS analysis using Thermo LTQ Orbitrap XL
connected to the nano-LC to determine the possibility of detection
of T-loop derived peptides. Analysis of recombinant CDK9/cyclin
T1 by MS/MS analysis showed good coverage of the CDK9
sequence, but the T-loop peptides were not detected (Fig. 4A).
Because ionization efficiency strongly depends on the peptide
structure, some peptides in principle may be ‘‘invisible’’ for the MS
analysis. Thus, we resorted to the Hunter peptide thin layer
electrophoresis followed by chromatography that resolves well
(
32P) phosphorylated peptides [29]. FLAG-tagged CDK9 was
expressed in 293T cells, metabolically labeled with (
32P) in the
presence of 0.1 mM okadaic acid and then immunoprecipitated
with anti-FLAG antibodies (Fig. 4B). CDK9 detected by
Coomassie staining and also by radioactivity was excised and in-
gel trypsinized. Tryptic peptides resolved by Hunter peptide
mapping system showed two major spots and one minor spot
(Fig. 4C, spots 1–3). The intensity of the spots 1 and 2 was greatly
reduced in the CDK9 S175A mutant (Fig. 4C) suggesting that at
Figure 2. Dephosphorylation of in vivo labeled CDK9 by PP1. (A) PP1 dephosphorylates CDK9 (
32P)-phosphorylated in cultured
cells. 293T cells transfected with Flag-CDK9 vector were pulsed with (
32P) orthophosphate in the presence of 100 nM okadaic acid. Flag-CDK9 was
immunoprecipitated with anti-Flag antibodies (lane 2) and subjected to dephosphorylation with PP1 (lanes 3 and 4), PP2A (lanes 5 and 6) or cdc25A
(lanes 7 and 8). Lane 1, immunoprecipitation with non-specific mouse IgG. The reactions were resolved on 10% SDS-PAGE and analyzed on Phosphor
Imager. (B) Comparison of phosphatase activities of PP1 and PP2A. Recombinant PP1 (0.1 U) and purified from human red blood cells PP2A
(0.1 U) were assayed with the generic KR-pT-IRR substrate or phospho-Rb peptide and the reactions were stopped at indicated time points by the
addition of malachite green solution. The amount of malachite green was quantified by the absorbance and recalculated into the phosphate
concentration using phosphate standard curve. (C) Dephosphorylation of CDK9’s Thr186 by PP1. 293T cells were transfected with vectors
expressing Flag-CDK9 WT (lanes 1–4) or Flag-CDK9 T186A (lane 5) and treated at 48 hours posttransfection with 100 nM okadaic acid. CDK9 was
immunoprecipitated from cellular lysates with anti-Flag antibodies, subjected to dephosphorylation with PP1 (lane 2) or PP2A (lane 4) and analyzed
by immunoblotting with phospho-specific CDK9 Thr186 or anti-CDK9 antibodies. (D) Comparison of dephosphorylation of (
32P) CDK9 and
Thr186-phosphorylated. Combined results from three independent experiments shown as percent of CDK9 dephosphorylation. *P,0.05. Results
are from a typical experiment of 4 performed.
doi:10.1371/journal.pone.0018985.g002
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further analyzed spots 1–3 by scraping the cellulose extracting the
peptides and subjecting them to the MS analysis. We detected ions
with the mass coinciding for the AFS
175LAK peptide as shown by
the elution of 318.69 Da ion in the raw base peak chromatography
data (Fig. 4D). The MS/MS data of this peak did not have enough
intensity to be positively identified by SEQUEST search. The spot
#3 showed MS/MS spectrum that allowed positive identification
of
346GSQITQQSTNQSR
358 peptide (Fig. 4E). To determine if
Spot#2 is a partially hydrolyzed Ser175-containing peptide, we
scraped the spot, trypsinized it overnight and rerun on the Hunter
system. After re-trypsinization, the Spot 2 migrated on the plate as
Spot 1 suggesting that indeed Spots 1 and 2 were the same
phosphopeptides. Taken together, these data strongly indicated
that CDK9 is phosphorylated on Ser175 in cultured cells.
Mutation of Ser175 prevents CDK9 dephosphorylation by
PP1
We further analyzed the dephosphorylation of CDK9’s Ser175
by utilizing WT CDK9 and CDK9 S175A mutant that were
expressed as FLAG-tagged constructs in cultured cells, labeled
with (
32P) orthophosphate in the presence of okadaic acid and
subjected to immunoprecipitation and dephosphorylation by PP1.
Phosphorylated CDK9 was efficiently dephosphorylated by PP1
(Fig. 5, lanes 1 and 2). Mutation of CDK9 in Ser175 reduced
overall level of CDK9 phosphorylation and but also made CDK9
S175A mutant insensitive to PP1 (Fig. 5, lanes 3 and 4). This result
suggests that Ser175 is targeted by PP1.
CDK9 S175A is enzymatically active and CDK9 S175D is
inactive
We next analyzed the effect of CDK9 Ser175 phosphorylation
on the activity of CDK9, using CDK9 S175A and CDK9 S175D
mutants. 293T cells were transfected with vectors expressing
FLAG-CDK9 (WT, S175A or S175D) and also co-transfected
with cyclin T1-expressing vector. CDK9 was immunoprecipitated
with monoclonal anti-FLAG antibodies and its activity was
analyzed using recombinant GST-CTD as substrate. Both WT
CDK9 and CDK9 S175A were active in the phosphorylation of
GST-CTD and were also autophosphorylated (Fig. 6A, lanes 1
and 2). In contrast, CDK9 S175D was inactive in CTD
phosphorylation and not autophosphorylated (Fig. 6A, lane 3).
To determine whether the inefficient kinase activity was due to
changes in the association with cyclin T1 or HEXIM1 protein, we
analyzed immunoprecipitated CDK9 mutants for the presence of
cyclin T1 and HEXIM1. The WT CDK9 and CDK9 mutants
associated approximately to the same extent with cyclin T1
(Fig. 6B, lanes 1–3), whereas association with HEXIM1 was
increased for CDK9 S175D mutant (Fig. 6B, lane 3), suggesting
that the inactivity of this mutant might be due to its increased
association with inhibitory 7SK snRNP. We next analyzed the
association of CDK9 mutant with cyclin T1 and HEXIM1 under
the condition of PP1 inhibition, which was achieved by the
expression of cdNIPP1. The WT CDK9 showed decreased
association with cyclin T1 and increased – with HEXIM1
(Fig. 6B, lane 4), in accord with our recent study that showed
increased 7SK snRNP formation in the cells expressing cdNIPP1
[20]. While CDK9 S175A showed decreased association with
cyclin T1, CDK9 S175D mutant had an increase in the cyclin T1,
but surprisingly, almost no HEXIM1, in contrast to WT CDK9
and S175A mutant CDK9 (Fig. 6B, lane 6). These results indicate
that Ser175 phosphorylation regulates CDK9 activity, and also
association with 7SK snRNP.
CDK9 S175A mutant activates HIV-1 transcription
We previously showed that PP1 activates HIV-1 transcription
[19]. If PP1 acts through the dephosphorylation of CDK9, then a
non-phosphorylatable mutant of CDK9 should activate HIV-1
transcription and its effect should no longer be dependent on the
presence of PP1. First, we analyzed the effect of different CDK9
mutants on Tat-induced HIV-1 transcription. Co-transfection of
the CDK9 mutants with HIV-1 LTR-LacZ and Tat –expression
vectors showed induction of HIV-1 transcription by CDK9 S175A
but not any other mutants tested (Fig. 7A). We have not seen
strong induction by CDK9 S175A and a strong inhibition effect by
the inactive CDK9 mutants T29E, S175D, T186A and C8A
(Fig. 7A), likely because the endogenous CDK9 compensated for
the inactive CDK9 mutants. To determine if the induction of
HIV-1 transcription by PP1 was lost with the CDK9 S175A
mutant, the 293T cells were co-transfected with PP1 expression
vector in combination with WT or mutant CDK9 and also HIV-1
LTR-LacZ and Tat –expression vectors. As a control, EGFP
expression vector was used. PP1 induced HIV-1 transcription in
the presence of WT CDK9 or CDK9 T29A mutant (Fig. 7B, lanes
1 and 2). In contrast, PP1 did not induced transcription beyond
Figure 3. PP1 dephosphorylates T-loop derived CDK9 peptide
phosphorylated on Ser 175. (A) Phosphorylation of CDK9’s T-
loop derived peptides. CDK7 or CDK9 T-loop derived peptides were
phosphorylated by recombinant CDK2/cyclin E or CDK9/cyclin T1,
resolved on 15% SDS Tric-Tricine gel and analyzed by Phosphor Imager.
Lanes 1 and 2, phosphorylation of CDK7 derived T-loop peptides by
CDK2/cyclin E. Lanes 4–7, phosphoryaltion of WT and mutant CDK9’s
T-loop-derived peptides by recombinant CDK9/cyclin T1. (B) Dephos-
phorylation of CDK9’s T-loop derived peptides by PP1. CDK9-
derived T loop WT peptides (lanes 1–3) or T186A mutant peptides
(lanes 4–6) were phosphorylated by recombinant CDK9/cyclin T1, then
CDK9 activity was blocked by 10 mM ARC and the peptides were
incubated with the indicated amount of PP1. The peptides were
resolved on 15% Tris-Tricine gel and analyzed by Phosphor Imager
(upper panel) and also showed stained with Coomassie Blue (lower
panel). Results are from a typical experiment of 3 performed.
doi:10.1371/journal.pone.0018985.g003
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(Fig. 7B, lane 4). Also, PP1 had no effect on HIV-1 transcription
in the presence of CDK9 S175D and CDK9 T186A (Fig. 7B,
lanes 5 and 6). The CDK9 T186A mutant is inactive [28] and thus
may act as dominant negative to inhibit HIV-1 transcription. The
CDK9 S175D is also inactive as kinase as we showed above and
thus may act in a manner similar to the T186A mutant. CDK9
mutants and Tat were expressed in the absence of PP1 (Fig. 7C,
lanes 1–7) and in the presence of PP1 (lanes 8–12). There was a
slight reduction of Tat expression in the cells expressing CDK9
mutants and PP1 (Fig. 7C, lanes 9–12). We next analyzed the
effect of CDK9 mutants on basal HIV-1 transcription. Co-
transfection of the CDK9 mutants with HIV-1 LTR-Luc showed
induction of HIV-1 transcription by CDK9 S175A (Fig. 7D).
Taken together, our results show that PP1 activates CDK9 and
that this activation could be through the dephosphorylation of
Ser175, mutation to alanine of which activated CDK9 enzymatic
activity and induced HIV-1 transcription.
Discussion
In a recent study, dephosphorylation of Thr 186 by PP1a was
shown to disrupt the interaction between CDK9/cyclin T1 and
7SK RNA/HEXIM1 when PP2B acted in cooperation with PP1a
[21]. If Thr186 was the only residue affected by PP1, then
inhibition of PP1 would increase Thr186 phosphorylation and
maintain the kinase activity of CDK9. In contrast, we observed
that inhibition of PP1 in nuclear extracts in vitro and in cultured
cells inhibited RNAPII phosphorylation and downregulated
CDK9 kinase activity. Our observation could not be explained
on the basis of only Thr186 dephosphorylation by PP1.
Comparison of the dephosphorylation of CDK9 metabolically
labeled with (
32P) in cultured cells with non-labeled CDK9 showed
that residues in addition to Thr186 are likely to be dephosphor-
ylated by PP1. Analysis of dephosphorylation of phosphopeptides
and also CDK9 S175A mutant suggested that CDK9’s Ser175
could be the additional dephosphorylation site. We analyzed
CDK9 phosphorylation sites by combining Hunter peptide thin
layer electrophoresis and LC-MS chromatography. In the cells
treated with okadaic acid CDK9 was phosphorylated on two sites,
which both were identified as Ser 175 containing phosphopep-
tides. Both of these sites were minimally phosphorylated in CDK9
S175A mutant. The third additional peptide which phosphoryla-
tion was not changed in the CDK9 S175 mutant was identified as
C-terminal
346GSQITQQSTNQSR
358 peptide. Recent study by
Johnson and colleagues showed that Ser
353 or Thr
354 are
autophosphorylated in vitro, in addition to the Thr
186 residue
which was also autophosphorylated [25]. Our previous study
showed that CDK9 autophosphorylated in vitro was dephosphor-
ylated by PP2A, but not PP1 [17]. We observed increased
autophosphorylation when CDK9 was pretreated in vitro with
PP2A but not PP1 [17]. PP2A, but not PP1, prevented the
interaction of CDK9/cyclin T1 with TAR RNA and Tat [17],
which was shown previously to be dependent on the autopho-
sphorylation of the C-terminal residues of CDK9 [15]. Thus, our
present study and the previous studies indicate that PP1 is not
likely to target the autophosphorylated sites of CDK9, and,
according to our data, Thr186 is not likely to be autopho-
sphorylated. While we observed phosphorylation of Ser175
peptide by CDK9, phosphorylation of the Thr186 was very poor
and may be due to a contaminating kinase. Interestingly, Johnson
and colleagues as well as Price and colleagues only detected
partially cleaved NSQPNRYpT
186NR peptide, but not the fully
trypsinized YpT
186NR peptide [25,28]. Our MS/MS analysis of
recombinant CDK9 showed very good coverage, but the T-loop
Figure 5. PP1 does not dephosphorylate CDK9 S175A mutant.
293T cells were transfected with vectors expressing Flag-tagged CDK9
WT (lanes 1, 2 and 5) or CDK9 S175A mutant (lanes 3 and 4) and treated
at 48 hours posttransfection with 100 nM okadaic acid and (
32P)
orthophosphate. CDK9 was immunoprecipitated from cellular lysates
with anti-Flag antibodies and subjected to dephosphorylation by PP1 as
indicated. Lane 5, immunoprecipitation with non-specific mouse IgG.
The reactions were resolved on 10% SDS-PAGE and analyzed on
Phosphor Imager and by immunoblotting with anti-CDK9 antibodies.
On a lower panel quantitation of (
32P) phosphorylation of CDK9 is
shown. Results are from a typical experiment of 2 performed.
doi:10.1371/journal.pone.0018985.g005
Figure 4. CDK9 is phosphorylated on Ser175 residue in cultured cells. (A) MS/MS analysis of recombinant CDK9. Recombinant CDK9/
cyclin T1 was resolved on 10% SDS-PAGE. CDK9 was identified by Coomassie staining, in-gel digested with trypsin, and the eluted peptides were
subjected to MS analysis on Thermo LTQ Orbitrap XL mass spectrometer as described in Materials and Methods. The SEQUEST search results are
shown. Green, peptides identified with high probability by MS/MS analysis. Red, peptides identified with less probability. Black, peptides that were
not detected. (B) purification of (
32P)-labeled CDK9 for the peptide fingerprint analysis. FLAG-tagged CDK9 was expressing in 293T cells
and metabolically labeled in the presence of okadaic acid. CDK9 was immunoprecipitated, resolved on 10% SDS-PAGE and stained with colloidal
Coomassie (upper panel), or exposed to Phosphor imager screen lower panel. Lane 1, mock-transfected cells. Lane 2, WT CDK9. Lane 3, CDK9 S175A
mutant. (C) Tryptic phosphopeptide mapping. (
32P)-labeled CDK9 was trypsinized and resolved on Hunter thin layer peptide mapping
electrophoresis system as described in Materials and Methods. WT CDK9 (upper panel) and CDK9 S175A (lower panel) are shown. Spots labeled as 1–3
were scraped and further analyzed by MS analysis. The results are representative from 2 experiments. (D) Base peak chromatography of Spot 1.
Raw base peak chromatography data showing ion with mass 318.69 that matches to AFSLAK (M+2H)
2+ peptide. Results are representative from 4
experiments.E.MS/MSspectrumofderivedfromSpot3.ThespectrumgivespositiveidentificationofGSQITQQSTNQSRpeptide.Resultsarefroma
typical experiment of 3 performed.
doi:10.1371/journal.pone.0018985.g004
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175LAK peptide
in the two spots resolved on Hunter thin layer electrophoresis, but
were not able to perform the MS/MS analysis of the peptide. It is
likely that the T-loop peptides are not well ionized and thus may
not be easily detected. Previously, Morgan and colleagues detected
CDK2-derived peptides by Hunter 2D peptide mapping system
but noted difficulties in detection of T-loop derived peptides due to
the strong binding of the peptides to the PVDF membrane [29]. A
comprehensive future analysis of CDK9 phosphorylation site
under different cellular conditions will need to employ more
sophisticated approaches such as additional peptide modifications
by MS tags or modification of the phosphate groups to create
better ionized peptides. In our study, CDK9 S175A mutant was
enzymatically active while CDK9 S175D mutant – inactive.
Accordingly, CDK9 S175A but not CDK9 S175D mutant
activated HIV-1 transcription. Our results are at variance with
the previously shown negative effect of CDK9 S175A mutation on
the GST-CTD phosphorylation [21] and also inability of CDK9
S175A mutant to activate HIV-1 transcription in vitro [30]. To
note, in yet another study, CDK9 S175A and CDK9 S175D
mutants were shown to be equally efficient in phosphorylating
Spt5 [28]. Reasons for the contradiction between our study and
other studies are not known. In stress-induced cells, CDK9/cyclin
T1 dissociates from 7SK RNA and HEXIM1, and interacts with
the bromodomain protein 4 (Brd4) [30,31]. Brd4, that interacts
with acetylated histones [32], recruits CDK9/cyclin T1 to various
cellular promoters. Both CDK9 S175A and CDK9 S175D
mutants do not bind to Brd4 [30], suggesting that phosphorylation
of Ser 175 might be important for the binding of CDK9/cyclin T1
to Brd4. We recently showed that expression of cdNIPP1 disrupts
the interaction of HIV-1 Tat with PP1, increases association of
CDK9 with 7SK snRNP and inhibits HIV-1 transcription and
replication data [20]. Our current results and recently published
data are summarized in the following model shown in Figure 8.
We adopted the concept of PP1 targeting by PP1-associated
proteins (PIPs) [33] to propose that different PP1/PIP complexes
might target PP1 to Thr 186 and Ser 175 residues of CDK9.
Dephosphorylation of CDK9 Thr 186 by PP1/PIP1 helps to
dissociate CDK9/cyclin T1 from 7SK snRNP [20]. The
dephosphorylation creates inactive CDK9 that is unphosphory-
lated on Ser175 and Thr186. Phosphorylation by a cellular
kinase(s) produces CDK9 phosphorylated on both Ser175 and Thr
186, which creates still inactive CDK9 because Ser175 phosphor-
ylation inactivates CDK9, according to our study. Our analysis of
phosphorylation of CDK9 peptides showed that Ser175 was much
more efficiently phosphorylated in cellular extracts suggesting a
possibility of preferential Ser175 over Thr186 phosphorylation.
CDK9 phosphorylated on Ser 175 can be targeted by a second
PP1/PIP2 complex which may or may not include Tat as Tat
contains a PP1-binding motif and thus might function a PIP [34].
The dephosphorylation of CDK9 Ser175 activates CDK9/cyclin
T1. The active CDK9/cyclin T1 may be recruited by Tat to
activate HIV-1 transcription. Alternatively, CDK9/cyclin T1 may
reassociate back with 7SK snRNP. The association with 7SK
RNA was shown to require the kinase acitive CDK9 [5,28],
suggesting that Ser 175 phosphorylated CDK9. Our model
Figure 6. CDK9 S175D mutation inhibits CDK9 kinase activity. 293T cells were transfected with the vectors expressing FLAG-tagged CDK9
WT, CDK9 S175A or S175D mutants along with the cyclin T1-expression vector (panel A) or with the inclusion of cdNIPP1 expression vector (panel D).
At 48 hours posttransfection, CDK9 was immunoprecipitated with anti-FLAG antibodies and analyzed for its kinase activity with GST-CTD substrate
(panel A) or by immunoblotting (panel B) with anti-CDK9, anti-cyclin T1 antibodies and HEXIM1 antibodies. Results are from a typical experiment of 3
performed.
doi:10.1371/journal.pone.0018985.g006
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the association of the mutant CDK9 with HEXIM1 suggesting
more efficient 7SK snRNP formation. The synergetic effect of PP1
and WT CDK9 on the activation of HIV-1 transcription was not
seen with CDK9 S175A mutant, suggesting that the effect of PP1
in HIV-1 transcription includes dephosphorylation of Ser 175A.
Our model proposes that in the absence of PP1, CDK9 Ser175-P
will not be able to associate with 7SK snRNP, the effect we
Figure 7. CDK9 S175A activates HIV-1 transcription. (A) Analysis of CDK9 mutants for the activation of HIV-1 transcription. 293T cells
were transfected with HIV-1 LTR-LacZ and Tat expression vectors along with the indicated WT or mutated Flag- CDK9. At 48 hours posttransfection b-
galactosidase activity was analyzed using ONPG substrate. Results are averages of quadruplicates from a typical experiment of 3 performed. (B) PP1
induction of HIV-1 transcription is reduced in the presence of CDK9 S175A mutant. 293T cells were EGFP (control) or PP1-EGFP expression
vector in combination with indicated WT or mutated Flag-tagged CDK9 and also with HIV-1 LTR-LacZ and Tat expression vectors. At 48 hours
posttransfection b-galactosidase activity was analyzed using ONPG substrate. Results are from a typical experiment of 3 performed. (C) Expression
of CDK9, PP1 and Tat. Protein expression from panels A and B was verified by immunoblotting.
doi:10.1371/journal.pone.0018985.g007
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however, explain why CDK9 S175D mutant in normal conditions
is seen associated with 7SK snRNP (Fig. 7B, lane 3). Perhaps, S to
D mutation only partially recapitulates the effect of phosphory-
lation. PP1 inhibition may also cause overphosphorylation of Thr
186 or phosphorylation of additional sites in CDK9. For example,
CDK9 T186E mutant does not activate HIV-1 transcription
(Fig. 7) and was reported to be inactive as kinase [12,28],
suggesting S to E mutation does not mimic the effect of Thr 186
phosphorylation. Another transcriptional activator, Tax binds
cyclin T1 and promotes autophosphorylation of CDK9 on Thr 29
rendering CDK9 inactive [13]. This Tax-mediated inactivation
might also prevent association of CDK9/cyclin T1 with 7SK
RNA and HEXIM1. In stress-induced cells, CDK9/cyclin T1 that
is dissociated from the 7SK RNA/HEXIM1 protein is bound to
Brd4 [30,31]. Recently Brd4 was shown to compete with Tax for
CDK9/cyclin T1 and it was proposed that Brd4 might inactivate
CDK9/cyclin T1 in a manner similar to Tax thus preventing re-
association of CDK9/cyclin T1 into the high molecular weight
complex [35]. Previous studies showed that the Tat-bound
CDK9/cyclin T1 is enzymatically active suggesting that CDK9
that is recruited by Tat is active in contrast to the Tax or Brd4
recruited CDK9/cyclin T1 [36,37]. Further detailed studies
needed to determine phosphorylation of CDK9 in the large P-
TEFb complex or in complex with transcriptional activaton.
Taken together, our study uncovered CDK9’s Ser 175 as new
target for PP1 thus providing further details on the regulation of
CDK9 activity by PP1 and suggesting PP1 for further evaluation
as a new therapeutic target.
Materials and Methods
Materials
293T and HeLa cells were purchased from ATCC (Manassas,
VA). 293T-cdNIPP1 cells stably expressing NIPP1 (143–224) were
previously described [20]. PP1 was purified from rabbit skeletal
muscle as previously described [38]. Recombinant PP1a was
purchased from New England Biolabs (Ipswich, MA). Human
protein phosphatase PP2A and cdc25A were purchased from
Upstate Biotechnology (Lake Placid, NY). Human recombinant
CDK9/cyclin T1 from baculovirus transfected Sf9 cells was
purified as described [39]. GST-CTD was purified as described
[40]. Okadaic acid and microcystin were from Sigma (Atlanta,
GA). The Rb-derived phosphopeptide HIPR-pS-PYKFPS-pS-
PLR (phospho-Rb) was synthesized by Synbiosci (Livermore, CA).
Peptides that span T-loop of CDK9 (WT:
172RAFSLAKNSQPN-
RYTNRVV
190, S175A:
172RAFALAKNSQPNRYTNRVV
190,
T186A:
172RAFSLAKNSQPNRYANRVV
190, and S175A/
T186A:
172RAFALAKNSQPNRYANRVV
190) and peptides that
span the T-loop of CDK7 (WT:
150KSFGSPNRIYTHQVV
165;
T160A:
150KSFGSPNRIYAHQVV
165) were purchased from New
England Peptides (Gardner, MA). Ser/Thr phosphatase assay kit
that included KR-pT-IRR peptide was purchased from Upstate
(Lake Placid, NY). Expression vectors for WT Flag-CDK9, CDK9
Figure 8. Proposed model of CDK9/cyclin T1 activation in viral transcription. CDK9’s Thr186 dephosphorylation by PP1/PIP1 complex leads
to the dissociation of 7SK RNA and HEXIM1 protein and the release of inactive CDK9. CDK9 is phosphorylated by a cellular kinase, which may include
active CDK9/cyclin T1 on Ser175 and Thr 186 that creates inactive CDK9/cyclin T1. This inactive phosphorylated CDK9/cyclin T1 is activated by PP1/
PIP2 complex. The active CDK9/cyclin T1 can be recruited by Tat or re-associated with 7SK snRNP.
doi:10.1371/journal.pone.0018985.g008
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substitutions of eight C-terminal serine and threonine (C8) were a
gift from Dr. Qiang Zhou (University of California, Berkeley).
Flag-CDK9 T29A, CDK9 T29E, CDK9 S175D and CDK9
T186E were created by mutagenesis using Quick-Change site-
directed mutagenesis protocol of Stratagene (La Jolla, CA), using
the appropriate primers and templates. The sequences of the DNA
constructs were verified by sequencing using a commercial service
from Macrogen (Rockville, MD). The expression vectors for
EGFP-fused central domain of NIPP1, NIPP1-(143–224) or
NIPP1-(143–224) V201AF203A (RATA mutant) were described
[23]. NIPP1 mutated within its RVXF motif have low binding
affinity for PP1 [23].
Antibodies
Anti-CDK9 phospho-Thr186 antibodies and anti-HEXIM1
antibodies were a gift from Dr. Qiang Zhou (University of
California, Berkeley). Rabbit polyclonal antibodies to CDK9,
rabbit polyclonal antibodies to cyclin T1 and rabbit polyclonal
antibodies to EGFP were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA). Anti-Flag monoclonal antibodies were
purchased from Sigma (Saint Louis, MO). Monoclonal antibodies
specific to the unphosphorylated form of CTD (8WG16) or CTD
phosphorylated on Serine 2 (H5) were purchased from BabCo
(Richmond, CA).
CDK9 phosphorylation in vivo and dephosphorylation
assays
293T cells were transfected with FLAG-CDK9-expression vector
using Lipofectamine and Plus reagents (Life Technologies). After
48 hours incubation, the cells were placed in a phosphate-free
DMEMmedia(LifeTechnologies)containingnoserumfor2 hours.
The media was changed to phosphate-free DMEM media
supplemented with 0.5 mCi/ml of (
32P)-orthophosphate and cells
were further incubated for 3 hours at 37uC. To increase CDK9
phosphorylation, 0.1 mM okadaic acid (Sigma) was added to block
cellular PPP-phosphatases.Cells were washedwithPBS andlysed in
a whole cell lysis buffer containing 50 mM Tris-HCl, pH 7.5,
0.5 M NaCl, 1% NP-40, 0.1% SDS and protease inhibitors cocktail
(Sigma). After 10 min on ice, cellular material was scraped,
incubated at 4uC for 30 min on a shaker and then centrifuged at
14,000 rpm, 4uC for 30 min. The supernatant was recovered and
protein concentration was determined using Lowry protein assay
(Bio-Rad). CDK9 was precipitated with monoclonal anti-Flag
antibodies (Sigma) coupled to protein G-agarose for 2 h at 4uCi na
TNN Buffer containing 50 mM Tris-HCl, pH 7.5, 0.15 M NaCl,
and 1% NP-40. The immunoprecipitated CDK9 was washed twice
with TNN buffer and then with phosphatase reaction buffer
(10 mM Tris-HCl pH 7.5, 0.02 mM EDTA, 0.5 mM DTT, 5 mM
caffeine, 0.01% NP-40 and 0.01% BSA) and incubated in the
phosphatase reaction buffer with 0.01 or 0.1 Units of PP1, PP2A,
cdc25A or non-treated (control sample) for 30 min at 30uC. Then
the reactions were stopped with SDS-loading buffer, resolved on
10% SDS-PAGE (Novex, Invitrogen) and subjected to autoradiog-
raphy and quantification with PhosphorImager Storm 860
(Molecular Dynamics). Analysis of CDK9 phosphorylation and
dephosphorylation on Thr186 was carried out in the same way
except that CDK9 phosphorylation was detected by immunoblot-
ting with phospho-specific Thr186 antibodies.
PP1 and PP2A dephosphorylation assays
The assays were carried out with the Ser/Thr phosphatase
assay kit (Upstate). PP1 or PP2A was added in PP1 reaction buffer
(50 mM HEPES pH 7.5, 100 mM NaCl, 2 mM dithiothreitol,
0.1 mM EGTA, 0.025% Tween-20) supplemented with 1 mM
MnCl2 (New England Biolabs) that also contained 150 mM KR-
pT-IRR or phospho-Rb peptide. At indicated time points, 25 ml
aliquots were removed and mixed with 100 ml of Malachite Green
solution. Absorbance of malachite green was determined at
620 nm and the phosphate concentration was recalculated using
a calibration curve of phosphate standards prepared using 1 mM
KH2PO4 solution.
Phosphorylation of RNAPII CTD in HeLa nuclear extract
RNAPII was phosphorylated in transcription reactions (20 ml)
containing 50 mg of HeLa nuclear extract, 0.5 mM ATP, CTP,
UTP and GTP, 0.2 mg of JK2 [41] linearized template in buffer C
(20 mM HEPES, pH 7.9, 50 mM KCl, 6.25 mM MgCl2, 0.5 mM
EDTA, 2 mM DTT and 10% glycerol). Transcription was carried
out for 30 minutes at 30uC. The reaction was terminated by
addition of 7 mM EDTA.
RNAPII labeling with (
32P) orthophosphate and Western
blots
293T cells were transiently transfected with vectors expressing
EGFP-fused NIPP1 (143–224) or NIPP1 (143–224) V201AF203A
(RATA mutant). At 24 hours posttransfection, the cells were pulse-
labeled with (
32P)-orthophosphate as described above and RNAPII
was immunoprecipitated with anti-CTD 8WG16 monoclonal
antibodies coupled to protein G agarose. The immunoprecipitated
RNAPII was recovered by heating for 2 min at 100uC in SDS-
loading buffer, resolved on 6% SDS-PAGE and the dried gel was
exposed to Phosphor Imager screen (Packard Instruments, Well-
esley, MA). In a control, the gel was transferred to a polyvinylidene
fluoride (PVDF) membrane and analyzed with anti-RNAPII CTD
8WG16 antibodies.
Phosphorylation of GST-CTD by CDK9 mutants in vitro
293T cells were seeded in 6-well plate and transfected with a
combination of plasmids expressing CyclinT1 and FLAG-CDK9
(WT, S175A or S175D) using Lipofectamine-LTX (Invitrogen). At
48 hours posttransfection the cells were washed with PBS and
lysed in a whole cell lysis buffer for 30 minutes. To precipitate
chromatin the samples were centrifuged at 14,000 rpm at 4uC for
90 minutes. The lysates were equalized for protein concentration
and diluted to 150 mM NaCl. CDK9 was immunoprecipitated
with monoclonal anti-Flag antibodies bound to protein G agarose
beads for 2 hrs at 4uC in TNN Buffer (50 mM Tris-HCl, pH 7.5,
0.15 M NaCl and 1% NP-40). The beads with precipitated CDK9
were washed with PBS and used for the kinase activity assay using
GST-CTD as substrate in 50 mM HEPES-KOH buffer (pH 7.5),
10 mM MgCl2, 6 mM EGTA, 2.5 mM DTT, 100 mM cold ATP
and 5 mCi c-(
32P)ATP for 30 minutes at 30uC. The reactions were
stopped with Laemmli sample buffer, resolved on 10% Tris-
Glycine SDS-PAGE (Novex, Invitrogen, Carlsbad, CA) and
subjected to autoradiography and quantification with Phosphor
Imager (Packard Instruments, Wellesley, MA).
Phosphorylation of CDK9- and CDK7- derived peptides in
vitro
About 2 mg of peptides that span T-loop of CDK9 or CDK7 as
indicated were phosphorylated in 50 mM Hepes-KOH buffer
(pH 7.5), 10 mM MgCl2, 6 mM EGTA, 2.5 mM DTT, 100 mM
cold ATP and 5 mCi c-(
32P)ATP for 30 minutes at 30uC. The
reactions were stopped with Laemmli sample buffer, resolved on
15% Tris-Tricine SDS-PAGE and subjected to autoradiography
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Wellesley, MA).
Tryptic phosphopeptide mapping
Tryptic phosphopeptide mapping was conducted using Hunter
thin layer peptide mapping electrophoresis system (C.B.S.
Scientific, Del Mar, CA). FLAG-CDK9 was expressed in 293T
cells and metabolically labeled with (
32P) orthophosphate as
described above. (
32P)-labeled FLAG-CDK9 WT and S175A
mutant were resolved on 10% SDS-PAGE. Radioactive bands
were visualized using Phosphor imager and excised from the gel.
The gel pieces were reduced in 10 mM DTT, alkylated with
30 mM iodoacetamide and then digested overnight with 10 ng/ml
Trypsin Gold (Promega) in 50 mM ammonium bicarbonate. The
eluted peptides were applied to thin layer cellulose plates
(Boehringer Mannheim, Indianapolis, IN) and separated in first
dimension by electrophoresis at pH 1.9 (H2O-acetic acid–formic
acid, 900:78:22) conducted at 1000 V, 12 mA for 1 hrs and
followed by ascending chromatography in Phospho-Chromatog-
raphy buffer (n-butanol-pyridine-acetic acid-H2O, 75:50:15:60)
for 15 hrs. Cellulose plates were dried and exposed to Phosphor
imager screen. To determine the content of the tryptic
phosphopeptide, cellulose containing the phosphopeptides was
scraped and the peptides were eluted in 70 acetonytril with 0.1%
TFA. The eluted peptides were lyophilized, resuspended in 0.1%
formic acid and subjected to mass spectrometry analysis.
Mass spectrometry
Samples were loaded to PicoFrit C18 column and eluted for
60 min with 2% to 30% gradient of acetonytrile and flow rate
300 nL/min using Shimadzu Prominence Nano HPLC. The 1 FT
MS scan and 3 data dependent FT MS/MS scans were performed
on Thermo LTQ Orbitrap XL mass spectrometer on major multi
charged MS peaks with resolution 60000 in each event set. The
resulting set of MS/MS spectra were analyzed by SEQUEST
(Thermo) search with precursor and fragments tolerance 20 ppm.
These high resolution data and search criteria reduce amount of
false positives and dramatically decrease the search time.
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